GlassScriptPhysician profile
Ashish Saxena
NPI 1578882858
$55,374.49
in general payments reported to CMS, 2019-2025
30 companies · $22K in 2025
The $22K reported for 2025 was more than what 93% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,866 · 2020: $4,696 · 2021: $4,974 · 2022: $308 · 2023: $2,157 · 2024: $15K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $31K · Honoraria: $3,425 · Food and Beverage: $2,787 · Travel and Lodging: $1,589 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $30,568.70 |
| Honoraria | $3,425.00 |
| Food and Beverage | $2,787.36 |
| Travel and Lodging | $1,589.31 |
| Education | $160.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $17,551.97 | 2024-2025 | Rybrevant |
| Astrazeneca Pharmaceuticals LP | $7,905.30 | 2019-2025 | Calquence, Enhertu, Lynparza |
| Galvanize Therapeutics, INC | $6,811.44 | 2024-2025 | Aliya System |
| Covidien LP | $5,101.66 | 2019 | |
| Novocure INC. | $3,677.33 | 2023-2024 | Optune Lua (Novottf-200t) |
| Roche Diagnostics Corporation | $3,474.00 | 2024 | |
| Genentech USA, INC. | $1,947.58 | 2019-2025 | Tecentriq, Alecensa, Phesgo |
| E.R. Squibb & Sons, L.L.C. | $1,930.00 | 2024 | Opdivo |
| Jazz Pharmaceuticals INC. | $1,923.35 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,873.88 | 2019-2023 | Gilotrif |
| Blueprint Medicines Corporation | $1,662.50 | 2020 | |
| Daiichi Sankyo INC. | $486.58 | 2021-2024 | Enhertu |
| Merck Sharp & Dohme LLC | $185.93 | 2019-2025 | Keytruda |
| Astrazeneca Uk Limited | $135.00 | 2025 | Datroway |
| Gilead Sciences, INC. | $111.94 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $111.38 | 2020-2024 | Lumakras |
| G1 Therapeutics, INC. | $104.50 | 2023 | Cosela |
| Takeda Pharmaceuticals U.S.A., INC. | $98.74 | 2024 | Alunbrig |
| Mirati Therapeutics, INC. | $71.55 | 2023-2024 | Krazati |
| Novartis Pharmaceuticals Corporation | $50.77 | 2022 | |
| Stemline Therapeutics INC. | $49.75 | 2025 | Orserdu |
| Coherus Oncology, INC. | $28.53 | 2023 | |
| Lilly USA, LLC | $21.20 | 2024 | Verzenio, Jaypirca |
| Array Biopharma INC | $20.96 | 2025 | Braftovi, Lorbrena |
| Alnylam Pharmaceuticals INC. | $19.90 | 2025 | Amvuttra |
| Genzyme Corporation | $18.75 | 2025 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Saxena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.